Novo valuation surpasses Tesla on experimental obesity drug data ...Middle East

Devdiscourse - Opinion
Novo valuation surpasses Tesla on experimental obesity drug data
Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug. Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.

Hence then, the article about novo valuation surpasses tesla on experimental obesity drug data was published today ( ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo valuation surpasses Tesla on experimental obesity drug data )

Apple Storegoogle play

Last updated :

Also on site :